CANAAN Research & Investment

Canaan Research & Investment is a South Korean biotechnology firm specializing in the discovery of first-in-class therapeutics for oncology and fibrotic disorders. The company was established by Dr. Sung-Jin Kim, a renowned expert in the TGF-beta signaling pathway, and serves as a core research engine for novel drug candidates. Canaan's pipeline includes innovative small molecules and monoclonal antibodies designed to modulate the tumor microenvironment and address conditions like cancer cachexia. As a major stakeholder in MedPacto, Canaan leverages its foundational research to fuel a broader ecosystem of clinical development. The company remains focused on high-risk, high-reward discovery projects that target unmet medical needs in immunology and metabolism. Their research strategy utilizes deep expertise in growth factor signaling to develop therapies that overcome immune evasion in advanced malignancies.